Imagenetix, Inc. Announces Interview With Bloom...( SAN DIEGO Aug. 17 /...)

SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), an innovator of scientifically tested, natural-based, proprietary products announced that last week Dr. Robert Hesslink, Director of Research & Development, was interviewed by Pimm Fox on his Bloomberg Radio program, Taking Stock. Dr. Hesslink discussed the bioceutical business of Imagenetix outlining the science behind its flagship product, InflameAway Celadrin(R), and 1-TDC, Imagenetix's early stage drug candidate for periodontal disease.

Dr. Hesslink, stated, "We had just announced publication of our second study on 1-TDC in the Journal of Periodontology so the timing of the interview was ideal."

The recent study on 1-TDC was conducted at Boston University Department of Periodontology and Oral Biology. The study results show that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration of tissue and bone health compared to the placebo group. The study was published in the July issue of The Journal of Periodontology and is also available online at:http://www.joponline.org/loi/jop (J Periodontal 2009; 80(7):1103-13).

To listen to the Bloomberg Radio interview, please follow this link: www.larrychendesign.com/iagxinterview.html

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multip
'/>"/>